Frequent mutations in SH2D1A (XLP) in males presenting with high-grade mature B-cell neoplasms.

abstract：BACKGROUND:Clinical outcomes of children with sickle cell disease (SCD) who undergo total or partial splenectomy (PS) are poorly defined. The purpose of this retrospective study was to initiate an Internet-based registry to facilitate analysis of clinical outcomes for these children. We hypothesized that both surgical ...

journal_title：Pediatric blood & cancer

authors： Mouttalib S,Rice HE,Snyder D,Levens JS,Reiter A,Soler P,Rothman JA,Thornburg CD

更新日期：2012-07-15 00:00:00

abstract：:The Standards, Options, and Recommendations (SOR) project undertaken by the French National Federation of Cancer Centers (FNCLCC) to develop and disseminate clinical practice guidelines in oncology has now been taken over by the French National Cancer Institute. In 2007, the SOR updated the information related to the ...

journal_title：Pediatric blood & cancer

authors： Marec-Berard P,Chastagner P,Kassab-Chahmi D,Casadevall N,Marchal C,Misset JL,Ray-Coquard I

更新日期：2009-07-01 00:00:00

abstract：BACKGROUND:Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies that occur throughout the lifespan. The impact of age on disease features and outcome is unclear. METHODS:We analyzed the clinical features and outcome of all STS cases registered between 1973 and 2006 in the SEER database. RE...

journal_title：Pediatric blood & cancer

authors： Ferrari A,Sultan I,Huang TT,Rodriguez-Galindo C,Shehadeh A,Meazza C,Ness KK,Casanova M,Spunt SL

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Information on the epidemiology of pediatric liver tumors in Latin America is limited. PURPOSE:To describe the incidence of liver tumors in a pediatric registry in Argentina according to geographic region, national trends over 16 years, and survival related to stage, age, sex, and care center. METHODS:Newl...

journal_title：Pediatric blood & cancer

authors： Moreno F,Rose A,Chaplin MA,Cipolla MC,García Lombardi M,Nana M,Cervio G,Halac E,Viso M,Ayarzabal V,Bosaleh A,Liberto D,Sarabia E,Rizzi A,Morici M,Streitenberger P,de Dávila MTG

更新日期：2020-11-01 00:00:00

abstract：:A 4-year-old girl with Noonan syndrome (NS) and constitutive PTPN11 mutation presented with stage 4 neuroblastoma and was treated by intensive chemotherapy. During the treatment, cytogenetic analysis revealed the development of a hyperdiploid clone with duplication of the germline PTPN11 mutation in a morphologically ...

journal_title：Pediatric blood & cancer

authors： Chantrain CF,Jijon P,De Raedt T,Vermylen C,Poirel HA,Legius E,Brichard B

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Neuroblastoma is the most common extracranial pediatric solid cancer. Lung metastasis is rarely detected in children with newly diagnosed neuroblastoma. We aimed to describe the incidence, clinical characteristics, and outcome of patients with lung metastasis at initial diagnosis using a large international ...

journal_title：Pediatric blood & cancer

authors： Dubois SG,London WB,Zhang Y,Matthay KK,Monclair T,Ambros PF,Cohn SL,Pearson A,Diller L

更新日期：2008-11-01 00:00:00

abstract：:Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 antibody used for treating patients with CD33+ acute myeloid leukemia (AML). We report three young children (two infants and one toddler) with AML treated with GO 9 mg/m(2). Two received two doses at diagnosis alone with conventional chemotherapy and one received one...

journal_title：Pediatric blood & cancer

authors： Sayar D,Burstein Y,Bielorai B,Toren A,Dvir R

更新日期：2010-07-15 00:00:00

abstract：BACKGROUND:Carboplatin is the most effective drug in retinoblastoma but systemic clearance is variable in young patients. While most regimens use a flat dose, individualized targeting may provide a more adjusted systemic exposure. PATIENTS AND METHODS:We compared carboplatin doses between two groups of children with r...

journal_title：Pediatric blood & cancer

authors： Allen S,Wilson MW,Watkins A,Billups C,Qaddoumi I,Haik BH,Rodriguez-Galindo C

更新日期：2010-07-15 00:00:00

abstract：BACKGROUND:Epoetin alfa (EPO, PROCRIT) pharmacokinetics and pharmacodynamics were evaluated in children with malignant solid tumors receiving chemotherapy. PROCEDURE:Children initially received IV EPO 600 IU/kg (max dose 40,000 IU) or placebo once weekly for 16 weeks. Dose was increased to 900 IU/kg (max dose 60,000 I...

journal_title：Pediatric blood & cancer

authors： Freeman BB 3rd,Hinds P,Iacono LC,Razzouk BI,Burghen E,Stewart CF

更新日期：2006-10-15 00:00:00

abstract：BACKGROUND:The identification of hemophagocytosis (HPC) in tissue or bone marrow (BM) represents only one of 5/8 criteria needed for the diagnosis of hemophagocytic lymphohistiocytosis (HLH). Yet, confirmation of HPC in bone marrow aspirates (BMA) is often relied upon to make therapeutic decisions. There is no standard...

journal_title：Pediatric blood & cancer

authors： Gupta A,Tyrrell P,Valani R,Benseler S,Weitzman S,Abdelhaleem M

更新日期：2008-09-01 00:00:00

abstract：BACKGROUND:Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome. The mainstays of treatment involve chronic red cell transfusions, long-term glucocorticoid therapy, and stem cell transplantation. Systematic data concerning endocrine function in DBA are limited. We studied patients in the DBA R...

journal_title：Pediatric blood & cancer

authors： Lahoti A,Harris YT,Speiser PW,Atsidaftos E,Lipton JM,Vlachos A

更新日期：2016-02-01 00:00:00

abstract：BACKGROUND:Few studies have evaluated social determinants of outcomes disparities for children with acute lymphoblastic leukemia (ALL). We investigated the association of area deprivation index (ADI), a measure of neighborhood socioeconomic disadvantage, with overall survival (OS) among children and adolescents with AL...

journal_title：Pediatric blood & cancer

authors： Schraw JM,Peckham-Gregory EC,Rabin KR,Scheurer ME,Lupo PJ,Oluyomi A

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Outcomes for childhood brain tumors are now associated with a five-year survival rate of 75%. Endocrine effects of brain tumors are common, occurring in 43% of patients by 10 years from tumor diagnosis. Optimal timing of screening for endocrinopathies remains undefined. We aim to identify incidence and timin...

journal_title：Pediatric blood & cancer

authors： Lawson SA,Horne VE,Golekoh MC,Hornung L,Burns KC,Fouladi M,Rose SR

更新日期：2019-05-01 00:00:00

abstract：:Both hepatoblastoma and hypoplastic kidneys are rare in children. A review of all patients with hepatoblastoma treated at our institution between 1993 and 2011 revealed three cases of hepatoblastoma occurring in children with hypoplastic kidneys and significantly impaired renal function. Two patients were treated with...

journal_title：Pediatric blood & cancer

authors： Chan R,Mascarenhas L,Venkatramani R

更新日期：2014-08-01 00:00:00

abstract：:In Mexico, childhood cancer incidence and mortality have increased in the last decade. Through government actions since 2005, the Popular Medical Insurance (PMI) program for childhood cancer was created. The objective of PMI was to offer early cancer diagnosis, standardized treatment regimens, and numerous pediatric o...

journal_title：Pediatric blood & cancer

authors： Rivera-Luna R,Zapata-Tarres M,Shalkow-Klincovstein J,Velasco-Hidalgo L,Olaya-Vargas A,Finkelstein-Mizrahi N,Cárdenas-Cardós R,Aguilar-Ortiz MR

更新日期：2017-06-01 00:00:00

abstract：:A 6-year-old male with chronic granulomatous disease, who was transplanted with bone marrow and exhibited increasing mixed chimerism, subsequently received two donor lymphocyte infusions (DLI). Two weeks after the second DLI, the patient developed acute graft-versus-host disease (GVHD) and progressive pancytopenia tha...

journal_title：Pediatric blood & cancer

authors： Kato I,Umeda K,Awaya T,Yui Y,Niwa A,Fujino H,Matsubara H,Watanabe K,Heike T,Adachi N,Endo F,Mizukami T,Nunoi H,Nakahata T,Adachi S

更新日期：2010-02-01 00:00:00

abstract：BACKGROUND:As pegylated asparaginase is becoming the preferred first-line asparaginase preparation in the chemotherapy regimens of childhood acute lymphoblastic leukemia (ALL), there is a need to evaluate this treatment. METHODS:The aim of this study was to evaluate the pharmacokinetics of prolonged upfront biweekly P...

journal_title：Pediatric blood & cancer

authors： Tram Henriksen L,Gottschalk Højfeldt S,Schmiegelow K,Frandsen TL,Skov Wehner P,Schrøder H,Klug Albertsen B,Nordic Society of Pediatric Hematology and Oncology, NOPHO Group.

更新日期：2017-12-01 00:00:00

abstract：:This report by the Radiation Oncology Discipline of Children's Oncology Group (COG) describes the practice patterns of pediatric image-guided radiotherapy (IGRT) based on a member survey and provides practice recommendations accordingly. The survey comprised of 11 vignettes asking clinicians about their recommended tr...

journal_title：Pediatric blood & cancer

authors： Hua CH,Vern-Gross TZ,Hess CB,Olch AJ,Alaei P,Sathiaseelan V,Deng J,Ulin K,Laurie F,Gopalakrishnan M,Esiashvili N,Wolden SL,Krasin MJ,Merchant TE,Donaldson SS,FitzGerald TJ,Constine LS,Hodgson DC,Haas-Kogan DA,Mahaja

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Posterior fossa syndrome (PFS) is defined as the temporary and complete loss of speech after posterior fossa surgery. The goal of this study was to identify incidence and risk factors for PFS and to determine accompanying neurobehavioral and psychologic problems. PROCEDURE:Between May 2007 and April 2009, c...

journal_title：Pediatric blood & cancer

authors： Küpeli S,Yalçın B,Bilginer B,Akalan N,Haksal P,Büyükpamukçu M

更新日期：2011-02-01 00:00:00

abstract：PURPOSE:To report the final analysis of survival outcomes for children with newly diagnosed high-grade glioma (HGG) treated on the "Head Start" (HS) II and III protocols with chemotherapy and intent to avoid irradiation in children <6 years old. PATIENTS AND METHODS:Between 1997 and 2009, 32 eligible children were enr...

journal_title：Pediatric blood & cancer

authors： Espinoza JC,Haley K,Patel N,Dhall G,Gardner S,Allen J,Torkildson J,Cornelius A,Rassekh R,Bedros A,Etzl M,Garvin J,Pradhan K,Corbett R,Sullivan M,McGowage G,Stein D,Jasty R,Sands SA,Ji L,Sposto R,Finlay JL

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. PROCEDURE:Oral vorinostat was administered on days 1-5 and 8-12 of a 21-day cycle (starting dose 180 mg/m(2...

journal_title：Pediatric blood & cancer

authors： Muscal JA,Thompson PA,Horton TM,Ingle AM,Ahern CH,McGovern RM,Reid JM,Ames MM,Espinoza-Delgado I,Weigel BJ,Blaney SM

更新日期：2013-03-01 00:00:00

abstract：:We report two survivors of Wilms tumor (WT) who developed inflammatory myofibroblastic tumor (IMT). The first patient had IMT in the mainstem bronchus 1 year after WT therapy that included vincristine, dactinomycin, doxorubicin (VDA) and whole lung radiation therapy (XRT). The second patient had IMT in the cecum 7 yea...

journal_title：Pediatric blood & cancer

authors： Ortiz MV,Rossi CT,Hill DA,Guzzetta PC,Qureshi F,Dome JS

更新日期：2015-06-01 00:00:00

abstract：:Children with cancer are at risk of malnutrition, which can impair critical childhood processes of growth and development and contribute to poor health outcomes. Enteral nutrition can effectively ameliorate malnutrition or weight loss in children with cancer; however, published nutrition support algorithms contain min...

journal_title：Pediatric blood & cancer

authors： McGrath KH,Hardikar W

更新日期：2019-07-01 00:00:00

abstract：:A rare case of primary intestinal T-cell lymphoma (ITL) of an 8-year-old boy is reported. Medium- to large-sized tumor cells were betaF1+, CD3+, CD8+. TIA-1+, but CD4-, CD5-, CD30-, CD56-, CD20-, CD79a-, TdT-, consistent with an intraepithelial lymphocyte (IEL) origin. They showed monoclonal rearrangement of the T-cel...

journal_title：Pediatric blood & cancer

authors： Friedrich C,Schrum J,Chott A,Janka-Schaub G,Kabisch H

更新日期：2010-04-01 00:00:00

abstract：BACKGROUND:The objectives of this study were to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, and anti-tumor effect of irinotecan in pediatric patients with recurrent or refractory malignancies. PROCEDURE:Twenty-three patients between 1 and 21 years of age, with a solid...

journal_title：Pediatric blood & cancer

authors： Bomgaars L,Kerr J,Berg S,Kuttesch J,Klenke R,Blaney SM

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Males have a higher incidence of medulloblastoma (MB) than females, but the effect of gender on survival is unclear. Studies have yielded conflicting results, possibly due to small sample sizes or differences in how researchers defined MB. We aimed to determine the effect of gender on survival in MB using a ...

journal_title：Pediatric blood & cancer

authors： Curran EK,Sainani KL,Le GM,Propp JM,Fisher PG

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:In low- and middle-income countries, therapeutic options for advanced, refractory, or relapsing malignancies are limited due to local constraints such as cost of drugs, distance from oncology centers, and lack of availability of new anticancer drugs. Metronomics, which combines metronomic chemotherapy (MC) a...

journal_title：Pediatric blood & cancer

authors： El Kababri M,Benmiloud S,Cherkaoui S,El Houdzi J,Maani K,Ansari N,Khoubila N,Kili A,El Khorassani M,Madani A,Tazi MA,Ahid S,Hessissen L,Quessar A,Harif M,Khattab M,André N

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:A feature often seen in adolescent patients with cancer is a lengthy symptom interval, especially in comparison with children. It has been suggested that inadequate awareness of cancer risk among adolescents may play an important role in this study. METHODS:The Società Italiana Adolescenti con Malattie Onco...

journal_title：Pediatric blood & cancer

authors： Magni C,Segrè C,Finzi C,Veneroni L,Clerici CA,Massimino M,Casanova M,Martinella V,Chiaravalli S,Ricci A,Biondi A,Ferrari A

更新日期：2016-08-01 00:00:00

abstract：BACKGROUND:Veno-occlusive disease (VOD) is a major complication following hematopoietic stem cell transplantation (HSCT). Its diagnosis is based on clinical criteria, which have a limited sensitivity. Increased plasminogen activator inhibitor-1 (PAI-1) levels have been suggested as a marker of VOD. We aimed to prospect...

journal_title：Pediatric blood & cancer

authors： Sartori MT,Cesaro S,Peruzzo M,Messina C,Saggiorato G,Calore E,Pillon M,Varotto S,Spiezia L,Cella G

更新日期：2012-05-01 00:00:00

abstract：:Wiskott-Aldrich syndrome (WAS) is characterized by primary immunodeficiency, thrombocytopenia and eczema. Patients with WAS have an increased risk to develop tumors. Non-Hodgkin lymphoma (NHL) represents the most common malignancy occurring in WAS-affected patients, diffuse-large-B-cell lymphoma is the most frequently...

journal_title：Pediatric blood & cancer

authors： Coccia P,Mastrangelo S,Ruggiero A,Scalzone M,Rosolen A,Maurizi P,Riccardi R

更新日期：2012-08-01 00:00:00